Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.

Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC

Merck

Which of these two pharmaceutical giants is poised to produce healthier returns?

Better Buy: Eli Lilly vs. Merck

AbbVie

Allergan

Bristol-Myers

Celgene

Medicines

Novartis

Pfizer

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.

Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

ArQule

These companies have some important presentations scheduled for the last big oncology conference of the year.

3 Biotech Stocks With a Lot to Prove at ASH 2019

Johnson & Johnson

Which stock wins in a head-to-head matchup between these two healthcare giants?

Better Buy: Johnson & Johnson vs. Eli Lilly

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?

Which of these pharma titans is the better buy right now?

Better Buy: Eli Lilly (LLY) vs. Pfizer (PFE)

Eli Lilly & Co. LLY, +0.90% said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus.

Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus

Coupa Software

Intuitive Surgical

MGM Resorts

Tyson Foods

Steven Cohen (Trades, Portfolio), manager of Point72 Asset Management, disclosed last week that his firm’s top five new buys for the third quarter were MGM Resorts International (NYSE:MGM), Coupa Software Inc. (NASDAQ:COUP), Eli Lily and Co. (NYSE:LLY), Intuitive Surgical Inc. (NASDAQ:ISRG) and Tyson Foods Inc. (NYSE:TSN).

Steven Cohen’s Top 5 Buys in the 3rd Quarter

Which stock wins in a head-to-head matchup between these two big drugmakers?

Better Buy: Eli Lilly vs. AbbVie

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Provention Bio Inc

Tandem Diabetes Care

There are some highly promising diabetes treatments entering the market that investors should know about.

3 Top Diabetes Stocks to Watch in November

Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option

Ingredion

Kohl's

Ralph Lauren

UnitedHealth Group

These companies reported higher than expected profits in the third quarter and offer rich payouts.

5 Lagging Blue Chips That Can Lead as Investors Turn Bearish

Infosys

Six Flags

Value investing is all about being willing to buy solid companies when the market throws a sale.

Wall Street Has Given Up on These 3 Stocks - and That's a Huge Mistake.

Assured Guaranty

JPMorgan Chase & Co

Keurig Dr Pepper Inc

Insiders invest in JPMorgan, Eli Lilly, Keurig Dr Pepper and Assured Guaranty.

Top Insider Buys Highlight for the Week of Oct. 25

Thor Industries

Insider buying can be an encouraging signal for potential investors. The new earnings season has closed buy windows for many insiders.

Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries

Wall Street hasn't been impressed by the makers of Humira and Trulicity lately, but their long-term prospects look stronger.

Don’t Sleep on These 2 Pharmaceutical Stocks

Investors weren't impressed with the drugmaker's Q3 report. Should bargain hunters take advantage of this recent weakness in its shares?

Is Eli Lilly Stock a Buy? (LLY)

Colgate-Palmolive

Cisco Systems

These big stock charts highlight three value plays left behind in the market's shift away from growth stocks.
The post 3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive appeared first on InvestorPlace.

3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive

Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript

The big drugmaker seemingly did what it needed to do in Q3. Except for one thing.

Why Eli Lilly Stock Fell Despite Its Solid Q3 Earnings Beat

Eli Lilly and Co  third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4%.

Sales of Eli Lilly diabetes drug Trulicity fall short, shares drop

When Eli Lilly and Co. (NYSE: LLY) released its third-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had $1.48 in earnings per share (EPS) and $5.48 billion in revenue.

News for Eli Lilly Stock (LLY)